EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Emerging Therapies for Anaphylaxis

Melanie C Dispenza

Immunology and Allergy Clinics of North America · 2026-05 · 46 (2) · 357-371

DOI: 10.1016/j.iac.2026.01.012 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunology and Allergy Clinics of North America, 2026-05. Verfasst von Melanie C Dispenza. Beteiligte Einrichtung: Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, 5501 Hopkins Bayview Circle, Baltim…. Hauptthemen laut MEDLINE: Anaphylaxis. Die Arbeit nennt 105 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institutes of Health, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anaphylaxis can be caused by several different mechanisms. Novel therapies on the horizon target these numerous pathways, including tyrosine kinase inhibitors, recombinant allergen-specific blocking antibodies, and monoclonals targeting KIT or inhibitory receptors. This article discusses potential new therapies for both the prevention and treatment of anaphylaxis that are currently in clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnaphylaxisHumansImmunoglobulin EAntibodies, MonoclonalAnimalsProto-Oncogene Proteins c-kitProtein Kinase InhibitorsAllergensDesensitization, ImmunologicAnti-Allergic Agents

Stichwörter der Autor:innen

AnaphylaxisBruton tyrosine kinaseChronic urticariaFood allergyIgEKITKinase

Substanzen

Immunoglobulin EAntibodies, MonoclonalProto-Oncogene Proteins c-kitProtein Kinase InhibitorsAllergensAnti-Allergic Agents

Autor:innen und Institutionen

  • Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, USA. Electronic address: mdispen1@jhmi.edu.

Förderung

  • NIAID NIH HHS
  • National Institutes of Health
  • AstraZeneca
  • Melinta Therapeutics

Zitieren

APA

Dispenza, M. C. (2026). Emerging Therapies for Anaphylaxis. Immunology and Allergy Clinics of North America, 46(2), 357-371. https://doi.org/10.1016/j.iac.2026.01.012

Vancouver

Dispenza MC. Emerging Therapies for Anaphylaxis. Immunology and Allergy Clinics of North America. 2026;46(2):357-371. doi:10.1016/j.iac.2026.01.012

BibTeX
@article{Dispenza2026,
  author = {Dispenza, Melanie C},
  title = {Emerging Therapies for Anaphylaxis},
  journal = {Immunology and Allergy Clinics of North America},
  year = {2026},
  volume = {46},
  number = {2},
  pages = {357--371},
  doi = {10.1016/j.iac.2026.01.012}
}
Kostenlos starten →